S
Steven A. Pergam
Researcher at Fred Hutchinson Cancer Research Center
Publications - 152
Citations - 5450
Steven A. Pergam is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 27, co-authored 133 publications receiving 4266 citations. Previous affiliations of Steven A. Pergam include University of Washington & University of New Mexico.
Papers
More filters
Journal ArticleDOI
Understanding influenza vaccination rates and reasons for refusal in caregivers and household contacts of cancer patients
TL;DR: Patients felt strongly that caregiver vaccination was important, whereas caregivers’ decisions did not appear to be affected by the patients’ disease, and influenza vaccination has limited efficacy in cancer patients.
Journal ArticleDOI
Improving Appropriate Diagnosis of Clostridioides difficile Infection Through an Enteric Pathogen Order Set With Computerized Clinical Decision Support: An Interrupted Time Series Analysis.
Catherine Liu,Catherine Liu,Catherine Liu,Kristine F Lan,Elizabeth M Krantz,H. Nina Kim,Jacqlynn Zier,Chloe Bryson-Cahn,Jeannie D. Chan,Rupali Jain,John B. Lynch,Steven A. Pergam,Steven A. Pergam,Steven A. Pergam,Paul S. Pottinger,Ania Sweet,Ania Sweet,Estella Whimbey,Andrew Bryan +18 more
TL;DR: Computerized clinical decision support tools can improve C difficile diagnostic test stewardship without causing harm, and additional studies are needed to identify key elements of CCDS tools to further optimize C Difficile testing and assess their effect on adverse clinical outcomes.
Journal ArticleDOI
Blood and marrow transplantation during the emerging COVID-19 pandemic: the Seattle approach.
Masumi Ueda Oshima,Masumi Ueda Oshima,Masumi Ueda Oshima,Brenda M. Sandmaier,Brenda M. Sandmaier,Brenda M. Sandmaier,Effie W. Petersdorf,Effie W. Petersdorf,Effie W. Petersdorf,Mary E.D. Flowers,Mary E.D. Flowers,Mary E.D. Flowers,Geoffrey R. Hill,Geoffrey R. Hill,Geoffrey R. Hill,Stephanie J. Lee,Stephanie J. Lee,Stephanie J. Lee,Frederick R. Appelbaum,Frederick R. Appelbaum,Frederick R. Appelbaum,Paul A. Carpenter,Paul A. Carpenter,Paul A. Carpenter,K. Scott Baker,K. Scott Baker,K. Scott Baker,Laura Connelly-Smith,Laura Connelly-Smith,Laura Connelly-Smith,Andrea McCool,Suni Elgar,Steven A. Pergam,Steven A. Pergam,Steven A. Pergam,Catherine Liu,Catherine Liu,Catherine Liu,F. Marc Stewart,F. Marc Stewart,F. Marc Stewart,Marco Mielcarek,Marco Mielcarek,Marco Mielcarek +43 more
TL;DR: The unique circumstances and challenges encountered, the current state of the program amidst evolving COVID-19 cases in the authors' community, and the guiding principles for recovery are described, which may help inform how transplant programs respond to CO VID-19 and future pandemics.
Journal ArticleDOI
Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation: Pre-transplant predictors of survival, reactivation, and spontaneous clearance
Julian Lindsay,Julian Lindsay,Jad Othman,Ian Kerridge,Ian Kerridge,Keith Fay,William Stevenson,William Stevenson,Christopher Arthur,Sharon C.-A. Chen,Sharon C.-A. Chen,David C. M. Kong,Steven A. Pergam,Steven A. Pergam,Catherine Liu,Catherine Liu,Monica A Slavin,Monica A Slavin,Matthew Greenwood,Matthew Greenwood +19 more
TL;DR: In this paper, the authors analyzed 159 allogeneic hematopoietic cell transplant (alloHCT) recipients with 4409 quantitative CMV viral loads to determine pre-transplant predictors of CMV reactivation, clinically significant CMV infection, and survival using a standardized pre-emptive therapy approach to identify at-risk groups to target prevention strategies.
Posted ContentDOI
Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy
Carla S Walti,Andrea N. Loes,Andrea N. Loes,Kiel Shuey,Elizabeth M Krantz,Jim Boonyaratanakornkit,Jim Boonyaratanakornkit,Jacob Keane-Candib,Tillie Loeffelholz,Caitlin R Wolf,Justin J. Taylor,Rebecca Gardner,Rebecca Gardner,Rebecca Gardner,Dylan Green,Dylan Green,Andrew J. Cowan,Andrew J. Cowan,David G. Maloney,David G. Maloney,Cameron J. Turtle,Cameron J. Turtle,Steven A. Pergam,Steven A. Pergam,Helen Y. Chu,Jesse D. Bloom,Joshua A. Hill,Joshua A. Hill +27 more
TL;DR: The authors conducted a prospective observational study of the humoral immunogenicity of 2019-2020 inactivated influenza vaccines (IIV) in children and adults immediately prior to (n=7) or 13-57 months after CAR-T-cell therapy, as well as controls.